Beta-lactamase inhibitors fixed dose combination - Qpex Biopharma
Alternative Names: Beta-lactamase inhibitor/QPX2015-FDC; QPX-2015; QPX2015/Beta-lactamase inhibitor-FDCLatest Information Update: 11 Sep 2023
Price :
$50 *
At a glance
- Originator The Medicines Company
- Developer Qpex Biopharma
- Class Anti-infectives; Antibacterials; Beta-lactams
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in Australia (PO)
- 07 Oct 2020 Qpex Biopharma plans a phase I trial for Bacterial infections (In volunteers) in Australia (PO, capsule) (NCT04578873)
- 06 Jan 2020 The Medicines Company has been acquired by Novartis